Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
Patients with clinical benefits from prolonged trastuzumab treatment are likely to benefit from T-DXd. Similarly, HER2 IHC 3+, intestinal type lesions, and better mGPS (0 or 1) are associated with longer rwPFS. However, T-DXd should not be withheld even in patients without these factors, as a median PFS of 3.42 months was observed in those with the shortest prior trastuzumab exposure.
Authors
- T. Nishina
- Yasuhiro Kodera (ORCID: https://orcid.org/0000-0002-6173-7474)
- Hirotaka Konishi (ORCID: https://orcid.org/0000-0002-4899-8944)
- H. Kawakami
- Wataru Hashimoto (ORCID: https://orcid.org/0000-0003-0185-2371)
- Rin Inamoto
- Yukiya Narita (ORCID: https://orcid.org/0000-0002-8018-0077)
- Keiko Minashi (ORCID: https://orcid.org/0000-0003-1513-7117)
- K. Muro
- Mari Hagiwara (ORCID: https://orcid.org/0000-0002-3715-5159)
- Akitaka Makiyama (ORCID: https://orcid.org/0000-0002-4017-668X)
- Koki Nakanishi (ORCID: https://orcid.org/0000-0002-0629-798X)
- Naotoshi Sugimoto (ORCID: https://orcid.org/0000-0003-1995-5002)
- Motohiro Imano (ORCID: https://orcid.org/0000-0003-2242-4245)
- Kensei Yamaguchi (ORCID: https://orcid.org/0000-0001-6887-5709)
- Satoshi Morita (ORCID: https://orcid.org/0000-0002-4344-3317)
- H. Kume
- T. Kawakami
Institutions
- Daiichi Sankyo (Germany) (DE)
- Tohoku University (JP)
- Kyoto University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Shizuoka Cancer Center (JP)
- Kindai University Hospital (JP)
- Osaka International Cancer Institute (JP)
- Daiichi-Sankyo (Japan) (JP)
- Gifu University Hospital (JP)
- Chiba Cancer Center (JP)
- Nihonkai General Hospital (JP)
- Saitama Cancer Center (JP)
- Daiichi Sankyo (India) (IN)
- Aichi Cancer Center (JP)
- Shikoku Cancer Center (JP)
- Nagoya Medical Center (JP)
- Nagoya University (JP)
- Kindai University (JP)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100184
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Edwards Lifesciences
- Abbott Japan
- Merck KGaA
- Taiho Pharmaceutical
- EA Pharma Co., Ltd.
- Miyarisan Pharmaceutical
- BeiGene
- Boehringer Ingelheim Japan
- Kaken Pharmaceutical
- Eisai
- Astellas Pharma
- Shionogi
- Otsuka Pharmaceutical
- Teijin Pharma
- Yakult Honsha
- Ono Pharmaceutical
- Chugai Pharmaceutical
- MSD K.K.
- Eli Lilly Japan
- Bayer Yakuhin
- Daiichi Sankyo Company
- Daiichi Sankyo Europe